



ASX RELEASE

Second US oncologist joins Race scientific advisory team

24 October 2016, Perth, Australia: Race Oncology Limited (ASX: RAC) is pleased to announce that it has signed a consulting agreement with Prof Douglas Smith MD, a leading international oncologist and expert in hematologic malignancies including AML (Acute Myeloid Leukaemia). Based at Johns Hopkins Hospital in Baltimore Maryland, Prof Smith will advise Race Oncology on the clinical positioning and utility of Bisantrone in the treatment of AML as well as its future clinical development.

“Our board of scientific advisors now has two US key opinion leaders in AML,” said Race Oncology CEO, Peter Molloy. “This demonstrates the interest at a clinical and research level in Bisantrone, an agent that can address the important unmet medical need in AML.”

Douglas Smith MD is Professor of Oncology at Johns Hopkins University School of Medicine and is on the active staff of Johns Hopkins Hospital and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He earned his medical degree at the Medical College of Pennsylvania in Philadelphia, after which he completed residency at Strong Memorial Hospital in Rochester, New York. At the completion of his fellowship in Oncology at Johns Hopkins University, he joined the faculty in the Division of Hematologic Malignancies.

Prof Smith’s research focuses on leukaemia, including AML, and he has published extensively in the field. He has been involved in numerous clinical trials and has received several awards and honours for his work. He serves as an editor for numerous journals including *Journal of Clinical Oncology*, *Leukemia*, *Clinical Cancer Research* and *Leukemia Research*. In addition, he is an active member of American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research.

About Race Oncology

Race Oncology Limited is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company’s first important asset is a chemotherapy drug, called Bisantrone, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrone and has secured Orphan Drug Designation in the US. The Company’s goal is to complete final development of Bisantrone and bring this valuable cancer drug to market. Visit raceoncology.com for more information.

For more information, contact:

Peter Molloy
Managing Director

T: +61 (0) 3 9097 1656
M: plmolloy@raceoncology.com